Table 1 Patient demographics and clinical characteristics at study enrolment (safety analysis set)
Characteristics | Dapagliflozin (N = 2990) |
|---|---|
Age, yearsa | |
 No. (missing) | 2990 (0) |
 Mean (SD) | 52.6 (12.0) |
Male | |
 No. (missing) | 2990 (0) |
 No. (%) | 1966 (65.8) |
HbA1cb | |
 No. (missing) | 1286 (1722) |
 %, mean (SD) | 9.07 (2.0) |
FPG, mmol/L | |
 No. (missing) | 1314 (1676) |
 Mean (SD) | 10.22 (4.0) |
Body weight, Kg | |
 No. (missing) | 408 (2582) |
 Mean (SD) | 76.90 (13.9) |
Height, cm | |
 No. (missing) | 2879 (111) |
 Mean (SD) | 167.42 (8.2) |
BMI, Kg/m2 | |
 No. (missing) | 403 (2587) |
 Mean (SD) | 27.27 (4.0) |
Median (range) | 26.80 (16.9–45.2) |
BMI category, n (%)c | |
  ≤18.5 | 2 (0.5) |
  >18.5 and <24 | 64 (15.9) |
  ≥24 and <28 | 189 (46.9) |
  ≥28 | 148 (36.7) |
Waist circumference, cm | |
 No. (missing) | 255 (2635) |
 Mean (SD) | 96.21 (10.5) |
SBP, mmHg | |
 No. (missing) | 407 (2583) |
 Mean (SD) | 131.6 (15.6) |
DBP, mmHg | |
 No. (missing) | 407 (2583) |
 Mean (SD) | 81.0 (10.1) |
Total cholesterol, mmol/L | |
 No. (missing) | 1299 (1691) |
 Mean (SD) | 4.87 (1.6) |
HDL-C, mmol/L | |
 No. (missing) | 1297 (1693) |
 Mean (SD) | 1.15 (0.4) |
LDL-C, mmol/L | |
 No. (missing) | 1299 (1691) |
 Mean (SD) | 2.79 (1.05) |
Triglycerides, mmol/L | |
 No. (missing) | 1301 (1689) |
 Mean (SD) | 2.83 (3.2) |
eGFR, ml/min/1.73 m2 | |
 No. (missing) | 1298 (1692) |
 Mean (SD) | 126.3 (41.1) |
  <45 | 3 (0.2) |
  ≥45 and <60 | 25 (1.9) |
  ≥60 and <90 | 183 (14.1) |
  ≥90 | 1087 (83.7) |
Duration of T2DM, yearsd | |
 No. (missing) | 2932 (58) |
 Mean (SD) | 8.35 (7.1) |
Presence of cardiac disorders, n (%) | |
 ASCVD | 640 (21.4) |
 Heart failure | 37 (1.2) |
Concomitant antidiabetic medications, n (%) | |
 None | 152 (5.1) |
 Monotherapy | 2838 (94.9) |
 Dual therapy | 2240 (74.9) |
 Triple therapy | 1168 (39.1) |
Presence of diabetic complications | |
 No. (missing) | 2990 (0) |
 No. (%) | 1764 (59.0) |